-
Most Recent
Healthcare Stocks
Healthcare encompasses a wide range of organized services to prevent, treat, and diagnose medical needs and mental illnesses. The $336 billion market is expected to grow at a compound annual growth rate of 8% until 2030, demonstrating the necessity of adequate healthcare. Healthcare companies, ranging from retailer CVS to insurance giant UnitedHealth, provide these services to a massive customer base.
7 Recession-Resistant Stocks to Hold Onto for Dear Life in 2024
These seven recession-resistant stocks offer stability and potential growth even in challenging economic conditions.
7 Dependable Dividend Stocks for Long-Term Income
Explore the best dividend stocks for long-term income excelling in the healthcare, retail, tobacco and home improvement markets.
3 Pharmaceutical Stocks That Can Surge Higher Even if The Markets Correct
These are the pharmaceutical stocks to buy as they represent undervalued companies with a deep clinical pipeline that will support growth.
Other industries you might be interested in
Recent Healthcare Stocks Articles
Dow Takes Worst Bath in a Year — Wednesday’s IP Market Recap
The Dow fell a 52-week worst 313 points on Wednesday as the markets fell to a post-election hangover and unsettling economic news out of Europe.
China’s Diabetes Epidemic Boosts Big Pharma
The world's largest population of diabetics is growing alarmingly, and combating it raises the prospects for names like Merck, Novo Nordisk and Sanofi.
Novartis Flu Vaccine Ban: Who Wins?
Two of Novartis' flu vaccines have been banned in seven countries, but the market's reaction to the move may be a bit overdone. Here's why.
Biotechs Beat Q3 Earnings, Revenue Estimates
Amgen, Gilead Science and Questcor Pharmaceuticals posted third-quarter earnings and revenue that beat Wall Street forecasts.
Bristol-Myers, Eli Lilly Miss Q3 Forecasts, Shares Slide
Bristol-Myers Squibb and Eli Lilly reported third-quarter earnings that missed Wall Street estimates as generic competition slammed drug sales.
Should I Buy Abbott Labs? 3 Pros, 3 Cons
Success in a drug regimen meant to treat hepatitis C is buoying shares of Abbott Laboratories, but has the easy money in ABT shares already been made?
FDA Pulls Approval for a Generic Antidepressant
A generic version of antidepressant Wellbutrin has lost FDA approval after tests showed it less effective than the brand name drug at a certain dosage.
Woman’s $180 Stock Buy Balloons to $7M
Sometimes buy and hold REALLY does pay off. The late Grace Groner's purchase of three Abbott Labs shares in 1935 worked out well.
10 Hottest Small-Cap Stocks of 2012
These 10 small to midsize businesses have seen returns ranging from 210 to 670% in just nine months. See which sector makes up most of this high-flying crowd.
A Healthy Portfolio Is Heavy in Health Care
Investors would be foolish to ignore the massive demographic shift and growth potential that is boosting health care stocks right now.
Are You Missing the Biotech Boat?
Biotech stocks have been one of the market's best performing areas during the past year and beyond. Is it too late to catch this comet?
Healthcare M&A: A Trend Worth Following
The "urge to merge" is as strong as ever in the booming healthcare sector, and this stock could be the next top contender for a buyout.
Health Insurance in the Dow? Why Didn’t We Think of That?
UnitedHealth's inclusion in the Dow Jones Industrial Average makes plenty of sense, but don't get giddy about a meaningful pop.
Who Has the Best Pharma Pipeline?
A look through Big Pharma's drug pipelines shows a lot of promise across several companies, but one firm stands out as having big-time revenue growth potential.
Monsanto’s Genetically Modified Corn Losing Effectiveness
The Environmental Protection Agency says that a number of studies show that rootworms are developing resistance to Monsanto's genetically modified corn.
Believe In This M&A Mastermind
Including its Medicis deal, Valeant Pharmaceuticals has made 27 acquisitions in the past four-plus years -- and it's showing no signs of capsizing.
Bet on Biotech With ViroPharma
Biotech stocks are speculative picks. But if you're willing to take a risk, ViroPharma is the way to go.
Gilead Poised to Go From Good to Great?
Gilead faces a pivotal FDA decision on its HIV "quad" pill Monday. Even if it's not much better than what's available, approval would be good news for investors.
